|
UBXN7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.7168999999484E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.224990E-04 |
| Normal-vs-Stage2 |
3.5913000000054E-05 |
| Normal-vs-Stage3 |
1.40069999998715E-06 |
| Normal-vs-Stage4 |
5.61099999999426E-05 |
| Stage1-vs-Stage2 |
1.679820E-01 |
| Stage1-vs-Stage3 |
1.530970E-01 |
| Stage1-vs-Stage4 |
2.855400E-01 |
| Stage2-vs-Stage3 |
7.388000E-01 |
| Stage2-vs-Stage4 |
7.677000E-01 |
| Stage3-vs-Stage4 |
9.962800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.84850999999098E-05 |
| Normal-vs-AfricanAmerican |
1.060450E-01 |
| Normal-vs-Asian |
3.94449999999713E-05 |
| Caucasian-vs-AfricanAmerican |
2.242200E-01 |
| Caucasian-vs-Asian |
3.328800E-01 |
| AfricanAmerican-vs-Asian |
8.879600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.42360001143783E-09 |
| Normal-vs-Female |
6.27180000000171E-05 |
| Male-vs-Female |
2.066200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.242350E-03 |
| Normal-vs-Age(41-60Yrs) |
2.8158999999528E-06 |
| Normal-vs-Age(61-80Yrs) |
5.4949999994669E-07 |
| Normal-vs-Age(81-100Yrs) |
2.020000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.865600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.034300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.457160E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.964800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.246800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.231200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.692200E-02 |
| Classical-VS-Follicular |
8.033600E-04 |
| Classical-VS-Other |
9.534000E-02 |
| Classical-VS-Normal |
4.351800E-04 |
| Tall-VS-Follicular |
4.949800E-01 |
| Tall-VS-Other |
2.624600E-01 |
| Tall-VS-Normal |
9.53540000000475E-05 |
| Follicular-VS-Other |
5.503400E-01 |
| Follicular-VS-Normal |
2.83050000104978E-08 |
| Other-VS-Normal |
2.075800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.04669999948059E-07 |
| Normal-vs-N1 |
7.789100E-04 |
| N0-vs-N1 |
6.895000E-01 |
|
|
